Your browser doesn't support javascript.
Progress on SARS-CoV-2 3CLpro Inhibitors: Inspiration from SARS-CoV 3CLpro Peptidomimetics and Small-Molecule Anti-Inflammatory Compounds.
Zhu, Jiajie; Zhang, Haiyan; Lin, Qinghong; Lyu, Jingting; Lu, Lu; Chen, Hanxi; Zhang, Xuning; Zhang, Yanjun; Chen, Keda.
  • Zhu J; Shulan International Medical College, Zhejiang Shuren University, Hangzhou, People's Republic of China.
  • Zhang H; Zhejiang Chinese Medical University, Hangzhou, People's Republic of China.
  • Lin Q; Shulan International Medical College, Zhejiang Shuren University, Hangzhou, People's Republic of China.
  • Lyu J; Shulan International Medical College, Zhejiang Shuren University, Hangzhou, People's Republic of China.
  • Lu L; Shulan International Medical College, Zhejiang Shuren University, Hangzhou, People's Republic of China.
  • Chen H; Shulan International Medical College, Zhejiang Shuren University, Hangzhou, People's Republic of China.
  • Zhang X; Shulan International Medical College, Zhejiang Shuren University, Hangzhou, People's Republic of China.
  • Zhang Y; Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, People's Republic of China.
  • Chen K; Shulan International Medical College, Zhejiang Shuren University, Hangzhou, People's Republic of China.
Drug Des Devel Ther ; 16: 1067-1082, 2022.
Article in English | MEDLINE | ID: covidwho-1808738
ABSTRACT
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) currently poses a threat to human health. 3C-like proteinase (3CLpro) plays an important role in the viral life cycle. Hence, it is considered an attractive antiviral target protein. Whole-genome sequencing showed that the sequence homology between SARS-CoV-2 3CLpro and SARS-CoV 3CLpro is 96.08%, with high similarity in the substrate-binding region. Thus, assessing peptidomimetic inhibitors of SARS-CoV 3CLpro could accelerate the development of peptidomimetic inhibitors for SARS-CoV-2 3CLpro. Accordingly, we herein discuss progress on SARS-CoV-2 3CLpro peptidomimetic inhibitors. Inflammation plays a major role in the pathophysiological process of COVID-19. Small-molecule compounds targeting 3CLpro with both antiviral and anti-inflammatory effects are also briefly discussed in this paper.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Protease Inhibitors / Peptidomimetics / Coronavirus 3C Proteases / COVID-19 Drug Treatment Limits: Humans Language: English Journal: Drug Des Devel Ther Journal subject: Pharmacology / Drug Therapy Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Protease Inhibitors / Peptidomimetics / Coronavirus 3C Proteases / COVID-19 Drug Treatment Limits: Humans Language: English Journal: Drug Des Devel Ther Journal subject: Pharmacology / Drug Therapy Year: 2022 Document Type: Article